Pfizer expands OTC portfolio with launch of OTC Nexium 24HR
- Pfizer is introducing OTC Nexium® 24HR, which will allow adult consumers to buy this top-selling medication for the relief of heartburn.
- Pfizer acquired global rights to OTC Nexium from AstraZeneca in August 2012 and received FDA approval on March 28, 2014 for Nexium 24HR.
- The launch of Nexium effectively grows Pfzier’s OTC portfolio, which now includes medications in four therapeutic categories.
Pfizer acquired worldwide rights to Nexium, one of the top-selling medications, from AstraZeneca in August 2012. In March 2014, FDA approved Nexium 24 HR as an OTC medication used to treat heartburn in adults. With 60 million affected adults, including 15 million who suffer from heartburn every day, the market for this product is strong. Pfizer’s OTC portfolio is growing, with medications in the following categories: respiratory therapy, pain management, dietary supplements and digestive therapy.
- World Pharma News Pfizer brings frequent heartburn relief OTC with new Nexium® 24HR